UK NMN Regulations: What You Need to Know in 2025

UK NMN Regulations: What You Need to Know in 2025

Nicotinamide mononucleotide (NMN) has become one of the UK's most sought-after longevity supplements. With its growing popularity comes increased regulatory oversight. This comprehensive guide explains the current UK legal framework for NMN supplements as of May 2025, essential reading for both consumers and supplement companies.

Legal Status in the UK

Is NMN Legal in the UK in 2025?

Yes, NMN remains legal to purchase and sell in the UK, subject to specific regulatory requirements. As a novel food, NMN requires pre-market authorisation to be legally sold in food supplements.

NMN is not prohibited but is subject to regulatory controls. All retailers and manufacturers must comply with novel food legislation and product safety standards under current UK law.

Understanding Novel Food Classification

Under UK legislation, a novel food is defined as any food or ingredient without significant history of consumption in the UK or EU before 15 May 1997. NMN falls within this category.

Consequently, all NMN-containing products intended for human consumption must undergo a formal novel food authorisation process through the Food Standards Agency (FSA). This process requires:

  • Comprehensive safety data
  • Detailed manufacturing specifications
  • Long-term stability studies

Regulatory Changes Following Brexit

Since the UK's departure from the EU, the UK has maintained the core EU novel food regulations but now administers its own approval process independently through:

  • The Food Standards Agency (FSA) for England, Wales and Northern Ireland
  • Food Standards Scotland

Current status (as of May 2025):

  • No NMN applications have received full approval in the UK
  • Products that were on the market before January 2021 may continue to be sold while "under assessment"
  • Products introduced after 2021 require complete authorisation or risk enforcement action

Current Position in the UK Novel Foods Catalogue

The UK Novel Foods Catalogue currently lists NMN as "under assessment." This means:

  1. Products containing NMN must not make unauthorised health claims
  2. NMN cannot be positioned as treating, preventing or curing any disease
  3. Products must be clearly labelled as food supplements, not medicines
  4. Daily dosage recommendations should align with established safety parameters (typically not exceeding 500mg daily unless clinically justified)

Will NMN Be Banned?

A complete ban appears unlikely. The FSA's approach indicates a preference for proper regulation rather than market removal. However, enforcement has become more stringent in 2025.

Brands may face regulatory action if they:

  • Fail to provide proper product labelling
  • Make medicinal claims about NMN
  • Do not engage with the novel food authorisation process

Importing NMN into the UK

For Personal Use

Individuals may import NMN for personal consumption, but customs authorities may intercept products that:

  • Lack proper labelling or ingredient disclosure
  • Originate from non-compliant manufacturing facilities
  • Make therapeutic claims on packaging or customs documentation

For Commercial Purposes

Businesses importing NMN for resale must ensure:

  • Products are properly registered with or declared to the FSA
  • Complete safety and purity documentation is readily available
  • Labelling complies with UK supplement standards, including:
    • Clear allergen information
    • Appropriate warnings
    • Batch identification
    • Expiry dating

Selecting a Compliant NMN Supplement in 2025

When purchasing NMN in the UK, look for these quality indicators:

✓ Certificate of Analysis (COA) from a UK-accredited laboratory
✓ Minimum 98% purity verified through independent testing
✓ Transparent ingredient listing with batch number and expiry date
✓ Manufactured in GMP-certified facilities
✓ Marketed strictly as a food supplement
✓ Properly registered or declared with the FSA as a novel food

Regulatory Compliance for UK Brands

UK supplement companies marketing NMN in 2025 must avoid:

❌ Making unauthorised health or medical claims (e.g., "treats ageing", "reverses disease")
❌ Providing inadequate labelling without clear dosage, purity, or manufacturing information
❌ Selling NMN without submitting appropriate novel food documentation
❌ Using marketing materials that comply with US regulations but not UK requirements

Companies that maintain transparent practices, conduct rigorous testing, and implement compliant labelling are significantly less likely to encounter regulatory issues.

Conclusion: Navigating the Regulatory Landscape

NMN remains legal in the UK but subject to increasingly defined regulation. As a consumer, prioritise brands that demonstrate transparency regarding purity testing and adhere to UK guidelines. If you're a retailer or manufacturer, ensure you've initiated the proper authorisation process and that all products meet FSA requirements.

Regulatory compliance not only protects businesses from potential enforcement but builds essential consumer trust in the expanding longevity supplement market.

Author: Mathew Stuckey
Founder, Healthspan Formulas
Longevity practitioner, product developer, and contributor to leading ageing and supplement networks across the UK and Europe.

Last updated: 18 May 2025

Back to blog